2-(4-METHOXYPHENOXY)-3-PYRIDINEAMINE, ITS PREPARATION AND ITS USE AS ANTI-INFLAMMATORY AGENT

Abstract: The product 3-amino-2-(4-methoxyphenoxy)pyridine and its pharmaceutically suitable salts, in particular the hydrochloride, are novel products which are prepared by catalytic hydrogenation of 2-(4-methoxyphenoxy)-3-nitropyridine, optionally in the presence of the acid corresponding to the salt. Its pharmaceutical compositions containing sufficient amounts of suitable auxiliaries for its topical administration prove particularly useful in therapy for the treatment of inflammatory skin diseases. The tests for dermatological action with the aid of TPA-induced mouse ear oedema and of carragenan-induced rat paw oedema show that the product is very much more active by the topical route than ibuprofen and nimesulide, two known anti-inflammatory active compounds, of which the first is very widely known and the second structurally related.

Description: 2-(4-methoxyphenoxy)-3-pyr1d1neam1 ne, Its preparation and Its use as antl' I nfl ammatory agent The present invention relates to a novel product, 3-amino-2- ( 4-methoxyphenoxy ) pyridine , a pharmaceutical composition containing this product , a process for its preparation and its therapeutic use , in particular as an anti-inflammatory active compound to be used topically. PRIOR ART Despite the large number of known pharmaceutical active compounds in the therapeutic area associated with inflammatory diseases, research and development of novel products and novel pharmaceutical application forms go on and on. This is in the main because of the fact that the non-steroidal, anti-inflammatory products on oral admini¬ stration bring with them the problem of side-effects in the gastrointestinal region. If the inflammation is superficial and locally restricted, it is attempted to keep these side-effects as small as possible by the topical administration of the product. Thus e.g. ibupro- fen (α-methyl-4-(2-methylpropyl)benzeneacetic acid), one of the most-used, orally administered, non-steroidal anti-inflammatory products, is likewise topically applied (cf. US-A-5 210 099 or US-A-5 104 656). The most related commercially available product to the present invention in its structure is presumably nimesulide or N-(4-nitro-2-phenoxyphenyl)methane- sulphonamide, which was first described in the document US-A-3 840 597. In this patent, its possible topical application in the form of a cream or of a gel is already mentioned. Its topical application in the form of an ointment is additionally the subject of the more recent patent EP-A-0 532 900. 3-Amino-2-(4-methoxyphenoxy)pyridine, to which the present invention relates, is generally described on page 7 of the Patent Application WO 92/13842 as a theo¬ retical possibility in a general formula of intermediary steps for the preparation of derivatives of the type N-(2-aryloxy-6-nitro)alkylsulphonamide. The preparation of this product and its features, however, are not expressly mentioned either in the said patent or in any other document, which is why it is a chemically novel product. DESCRIPTION OF THE INVENTION The object of the present invention is the preparation of 3-amino-2-(4-methoxyphenoxy)pyridine and its pharmaceutically suitable salts, among these par- ticularly preferably the hydrochloride. Besides 3-amino-2-(4-methoxyphenoxy)pyridine, the present invention additionally relates to pharmaceutical compositions which contain therapeutically active amounts of the product 3-amino-2-(4-methoxyphenoxy)pyridine or of pharmaceutically suitable salts thereof and sufficient amounts of suitable auxiliaries. The preferred auxil¬ iaries are found among those suitable for topical administration, in the form of creams, gels, ointments, unguents, eye drops and the like. The invention likewise includes the use of the product 3-amino-2-(4-methoxy- phenoxy)pyridine or a pharmaceutically suitable salt thereof in the production of medicaments for the treat¬ ment of inflammatory syndromes. Although3-amino-2-(4-methoxyphenoxy)pyridine, to which the present invention relates, can be administered orally, this product is especially preferred for topical application, which is why it has proven particularly suitable for the control of inflammatory skin and eye diseases, such as of allergic or photoallergic derma- titis, contact dermatitis, of sunburn, nettle-rash, eczema, atopic dermatitis, exfoliative dermatitis, psoriasis, etc. The present invention makes available a prepara¬ tion process for 3-amino-2-(4-methoxyphenoxy)pyridine, which is characterized in that 2-(4-methoxyphenoxy)-3- nitropyridine is catalytically hydrogenated in a suitable solvent. In a particular embodiment, the catalyst used is palladium on carbon and the solvent is ethyl acetate. The above starting material, 2-(4-methoxyphenoxy)-3- nitropyridine, is preferably obtained by reaction between 2-chloro-3-nitropyridine and the alkali metal salt of 4-methoxyphenol using toluene as a solvent. The pharmaceutically suitable salts of 3-amino-2-(4-methoxy- phenoxy) yridine are prepared by reaction with the corresponding acids either in situ or in consecutive steps. For the preparation of the hydrochloride, the hydrogenation process in the presence of hydrochloric acid in a mixture of ethyl acetate and ethanol is preferred. The anti-inflammatory action on topical adminis¬ tration of 3-amino-2-(4-methoxyphenoxy)pyridine was compared with that of known anti-inflammatory products whose use by the topical route has been described. To be precise on the one hand using ibuprofen as a classical, widely used product, even if structurally not very similar; and on the other hand using nimesulide as a newer, but structurally related product. Additionally, two standard tests for dermatological action were carried out, to be precise the TPA-induced mouse ear oedema and carragenan-induced rat paw oedema tests. In the first, the inhibitory action of the topically applied product on the oedema produced in the ear of the mouse by an appli- cation of 12-0-tetradecanoylphorbol (TPA) acetic acid ester is measured. In the second, the inhibitory action of the topically applied product on the oedema caused by subplantar injection of carragenan in the paw of the rat is measured. The results of these tests, which are listed in Table 1, show that 3-amino-2-(4-methoxy- phenoxy)pyridine has a surprisingly high anti- inflammatory action on topical application, much higher than that of the two reference products, which is a great advantage. Table 1: Anti-inflammatory action on topical application, expressed as the percentage decline in inflammation Product TPA test (1) Paw oedema test (2) Ibuprofen 16% 2.0% Nimesulide 27% 15% Product of the invention 32% 42% Product of the invention = 3-amino-2-(4-methoxyphenoxy)- pyridine (1) 250 μg/mouse ear. (2) 60 mg/rat paw The following Examples are intended to illustrate the invention. EXAMPLES Example 1; Preparation of 3-amino-2-(4-methoxyphenoxy ) - pyridine and its hvdrochloride 5.87 g of 4-methoxyphenol were dissolved in 8 ml of methanol; 2.61 g of KOH were added, the whole was stirred for 2 hours, and the solvent was evaporated. The solid obtained was dissolved in 150 ml of anhydrous toluene. With stirring, 5 g of 2-chloro-3-nitropyridine were added at 70-80°C in the course of 4 hours under a nitrogen atmosphere. The whole was then stirred at ambient temperature for 2 hours. It was washed with 10% aqueous NaOH and then with plenty of water. The organic phase was treated with active carbon at room temperature for 60 minutes. It was filtered and the filtrate was dried with anhydrous magnesium sulphate. After evapora¬ tion of the solvent at low pressure, 7.4 g of 3-amino-2- (4-methoxyphenoxy)pyridine (95% yield) were obtained as a pale yellow solid which melted at 105-107°C with decomposition. 6.40 g of the preceding product were dissolved in 160 ml of ethyl acetate; 100 mg of a suspension of palladium on active carbon containing 50% of water were added, which hydrogenated to complete conversion at 35 psi in the course of 90 min.. The whole was filtered, and after evaporation of the solvent and subsequent recrystallization in isopropanol 4.42 g (79%) of 3-amino- 2-(4-methoxyphenoxy)pyridine were obtained, which had a melting point of 144-147°C. By hydrogenation of the above product in a mixture of ethyl acetate and ethanol as a solvent and in the presence of concentrated hydrochloric acid, the hydrochloride of 3-amino-2-(4-methoxyphenoxy) yridinewas obtained as a white solid which melted at 140-142°C with decomposition. Example 2: Comparison test of the anti-inflammatorv. topical action bv the TPA-induced ear oedema test 1 μg of TPA (12-O-tetradecanoylphorbol acetate) in 20 μl of acetone was administered to the left ear of mice of both sexes of weight 25 ± 5 g. The solution containing 250 μg in each case of the medicament investigated (nimesulide, ibuprofen and 3-amino-2-(4- methoxyphenoxy) yridine in each case) was given in the right ear- After 6 hours, both ears were cut off and weighed and the percentage weight loss was measured, which on average gave the following values: 27% with nimesulide, 16% with ibuprofen and 32% with 3-amino-2-(4- methoxyphenoxy)pyridine. The procedure was essentially according to the method described by J.M . . Young and colleagues (J. Invest. Dermatol. 1983, Vol. 80, pp. 48-52), but the weight and not the size of the ear was measured. Example 3: Comparison test of the anti-inflammatory. topical action bv the carragenan-induced paw oedema test 600 mg of a gel was applied topically to the right hind paws of Wistar rats of both sexes of weight 150 ± 50 g, containing placebo in the case of the un¬ treated animals and containing 30 g of the medicament investigated (nimesulide, ibuprofen and 3-amino-2-(4- methoxyphenoxy)pyridine in each case) in the case of the others. After 45 minutes, all animals were given 0.05 ml of a 1% strength carragenan solution in physiological saline solution by the subplantar route, again in the right paw. Two hours later, the treatment was repeated to be with the medicament as above. One hour later, the percentage increase in the treated paw compared with the other was determined, both in the untreated animals and in those treated with the medicaments, the percentage weight losses being calculated, which on average appeared to be as follows: 15% with nimesulide, 2% with ibuprofen and 42% with 3-amino-2-(4-methoxyphenoxy)pyridine. The method described by CA. Winter and colleagues was mainly used (Proc. Soc. Exp. Biol. Med. 1962, Vol. Ill, pp. 544-547) with the modifications necessary for per¬ cutaneous administration of the medicament. A plethysmo- meter of the make Ugo Basile, Model 7150, was used.

Claims: CLAIMS 1. 3-Amino-2-(4-methoxyphenoxy)pyridine or a pharma¬ ceutically suitable salt thereof. 2. Hydrochloride of 3-amino-2-(4-methoxyphenoxy)- pyridine. 3. Pharmaceutical composition which contains a therapeutically active amount of 3-amino-2-(4-methoxy¬ phenoxy)pyridine or of a pharmaceutically suitable salt thereof, together with a sufficient amount of an auxil- iary or of auxiliaries. 4. Pharmaceutical composition according to Claim 3, characterized in that the auxiliary is selected from those customary for topical application. 5. Use of 3-amino-2-(4-methoxyphenoxy)pyridine or of a pharmaceutically suitable salt thereof for the produc¬ tion of a medicament for the treatment of inflammatory diseases. 6. Use according to Claim 5, characterized in that the inflammatory diseases are of dermatological type, and in that the medicament is topically administered. 7. Process for the preparation of 3-amino-2-(4- methoxyphenoxy)pyridine, characterized in that 2-(4- methoxyphenoxy)-3-nitropyridine is catalytically hydrog- enated in a suitable solvent. 8. Process according to Claim 7, characterized in that the catalyst used in the reaction is palladium on carbon and the solvent is ethyl acetate. 9. Process according to Claim 7, characterized in that the 2-(4-methoxyphenoxy)-3-nitropyridine is obtained by reaction between 2-chloro-3-nitropyridine and potas¬ sium 4-methoxyphenoxide using toluene as a solvent.

Inventors: ALDOMA GUSTAVO ENRIQUE, PIATTI SUSANA ELIDA, ALDOMA, GUSTAVO, ENRIQUE, PIATTI, SUSANA, ELIDA
Applicants: ALDOMA GUSTAVO ENRIQUE, HANDFORTH INVEST LTD, PIATTI SUSANA ELIDA, ALDOMA, GUSTAVO, ENRIQUE, HANDFORTH INVESTMENTS LTD., PIATTI, SUSANA, ELIDA
Application year: 1995
Main classification: C07D213
IPC codes: A61K31, A61P17, A61P29, C07D213